Aurintricarboxylic acid strongly inhibits rP2X1Rs and rP2X3Rs with IC ₅₀ values of 8.6 nM and 72.9 nM, respectively, and more weakly inhibits P2X2/3Rs, P2X2Rs, P2X4Rs or P2X7Rs.
Aurintricarboxylic acid inhibition of ATP-induced currents is concentration dependent.
Aurintricarboxylic acid is a non-competitive antagonist of P2X3R.
Aurintricarboxylic acid can inhibit the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) and vaccinia virus.
Aurintricarboxylic acid protects MDCK cells from infection with influenza A strains PR8, NY or N.
Aurintricarboxylic acid inhibits replication of influenza A and B viruses.
Aurintricarboxylic acid inhibits neuraminidase activities of influenza A and B viruses.
Aurintricarboxylic acid inhibits TWEAK-Fn14-mediated NF-κB activation.
Aurintricarboxylic acid (10 μM;0.5-2 hours) suppresses TWEAK-Fn14-mediated NF-κB, Akt, and Src phosphorylation in GBM cells.
Aurintricarboxylic acid blocks TWEAK-stimulated Rac1 activation and TRAF2 recruitment to Fn14 cytoplasmic domain in glioma cells.
Aurintricarboxylic acid represses TWEAK-stimulated glioma cell migration and invasion without causing cell cytotoxicity.
Aurintricarboxylic acid (Compound 8) cannot regulate loading of endogenous let-7 onto AGO2 inside cultured cells, whereas can inhibit RISC loading of exogenous siRNA.